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Abstract 
Purpose.  Fluoroquinolones are generally considered safe and well-tolerated.  However, 
suspected fluoroquinolone induced hepatotoxicity has been increasingly reported, but 
data are lacking.  Thus, the objective of this study was to assess the risk of 
hepatotoxicity in patients using fluoroquinolones compared to non-users. 
 
Methods.  National Veterans Affairs (VA) hospital admissions were assessed between 
January 1, 2002 and December 31, 2008.  Our case-control study matched patients with a 
primary diagnosis of hepatotoxicity (cases) to those with myocardial infarction 
(controls) on admission date (matched up to 1:6).  Conditional logistic regression was 
used to compute adjusted odds ratios (OR) and 95% confidence intervals (CI) of 
hepatotoxicity associated with fluoroquinolone exposure.  
 
Results.  Our study included 7,862 cases and 45,512 matched controls.  The majority of 
study patients were white (63.4%), males (97.7%), with a mean age of 61 years.  After 
adjusting for confounders, fluoroquinolone use was significantly associated with a 20% 
increased risk of hepatotoxicity development (OR 1.20, 95% CI 1.04-1.38) compared to 
non-users.  A statistically significant increased risk of hepatotoxicity was associated 
with ciprofloxacin use individually (OR 1.29, 95% CI 1.05-1.58), but not with 
levofloxacin or moxifloxacin use. 
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Conclusion.  The use of fluoroquinolones was associated with an increased risk of 
hepatotoxicity relative to non-users in our national VA study population. 
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Purpose  
Fluoroquinolones have had a major impact on the treatment of moderate-to-severe 
infections ever since their introduction over 20 years ago.1  They are used extensively 
worldwide, in both community and nosocomial settings, because of their broad-
spectrum bactericidal activity, clinical utility, excellent oral bioavailability, and ease of 
dosing.2  Further adding to their appeal is their favorable side effect profile.  
Fluoroquinolones are generally well tolerated, with the most common adverse effects 
being mild and reversible gastrointestinal and central nervous system reactions.3 
Despite their popularity, fluoroquinolone antibiotics are not exempt from serious 
safety concerns, including a potential risk of hepatotoxicity.4  Mild, transient elevations 
in aminotransferase are considered a class effect, however severe liver toxicity 
potentially associated with fluoroquinolone use is relatively rare.4  With the exception of 
trovafloxacin, which was removed from the marked due to a strong association 
between the drug and fatal acute liver failure, the literature supporting fluoroquinolone 
induced hepatotoxicity is scant, mostly limited to case reports and reviews.5-14  
However, there have been selected reports of death from suspected fluoroquinolone 
induced hepatic failure, thus this toxicity remains an important concern.15-17   
 The association between fluoroquinolones and hepatotoxicity remains unclear 
and epidemiologic studies are needed to further assess this risk.  Recently, a case-
control study of elderly Canadian outpatients demonstrated an increased risk of acute 
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liver injury associated with moxifloxacin and levofloxacin use.18   Further real-world 
safety studies are necessary to confirm these results. As such, we conducted a case-
control study to assess the risk of hepatotoxicity associated with fluoroquinolone use 
(ciprofloxacin, levofloxacin, and moxifloxacin) among adult patients admitted to 
Veterans Affairs (VA) facilities nationally.  
 
Methods 
Study design and data source. 
We used a retrospective, matched case-control design using data extracted from 
national Veterans Affairs (VA) databases capturing clinical care from electronic medical 
records.  The Veterans Health Administration is the largest integrated healthcare system 
in the United States and includes 152 acute care hospitals and over 800 outpatient 
clinics, which are located throughout the country.19  Each year over 5.5 million Veterans 
are treated at VA facilities.  
 The VA has used and electronic medical record since 1999, and at each facility 
inpatient and outpatient care is captured and compiled into national databases.  These 
databases include data on diagnoses, as documented with International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnostic and procedure codes, 
demographics, provider characteristics, vital status, inpatient and outpatient 
prescriptions, laboratory tests performed, select laboratory results, and vital 
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measurements.20, 21  The design and methods were defined a priori in the study protocol, 
which was approved by the medical center’s and university’s Institutional Review 
Boards. 
 
Case and control identification. 
We identified cases from VA hospital admissions between January 1, 2002 and June 30, 
2008 with a primary diagnosis for hepatotoxicity, defined as hepatic necrosis (ICD-9-
CM 570) and toxic hepatitis (ICD-9-CM 573.3).22, 23  Patients with a known cause of 
hepatotoxicity or a history of liver disease were excluded including individuals with 
ICD-9-CM codes (Table 1) for liver cirrhosis, liver cancer, viral hepatitis (including 
types A, B, C, D, or E), alcoholic hepatotoxicity, acetaminophen induced-hepatotoxicity, 
human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome 
(AIDS), liver abscess, and Wilson’s disease.  Additionally, to avoid possible 
confounding effects from recent illness, patients who were hospitalized during the 180 
days prior to the admission date were excluded.  If patients had multiple admissions for 
hepatotoxicity during the study period, only the first episode was assessed.  For all 
analyses, the date of admission served as the index date. 
Controls were defined as hospitalized patients with a primary diagnosis of 
myocardial infarction (ICD-9-CM 410.00-410.92).  As with acute liver injury, myocardial 
infarctions are acute events with potentially serious outcomes.  Patients with these 
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conditions usually have the similar care and treatment, which differ from treating more 
chronic conditions.  Due to the similarities between the conditions, a control group of 
patients experiencing myocardial infarction was identified.    Further, patients with 
myocardial infarction were selected as controls in an attempt to have the exposure 
independent from the outcome. Controls were randomly selected using case-base 
sampling from the source population.  Up to six controls were matched to each case on 
hospital admission month and year.   
Data analyses. 
The purpose of our primary analysis was to quantify the association between exposure 
to fluoroquinolone antibiotics on the development of hepatotoxicity.  Exposure to 
fluoroquinolones was defined as outpatient prescriptions for ciprofloxacin, 
levofloxacin, or moxifloxacin in the six months prior to the admission date. 
Demographic and clinical characteristics of cases and controls were analyzed 
using chi-square or Fisher’s exact tests for categorical data and the Student’s t-test or 
Mann-Whitney U-test for continuous data.  We used conditional logistic regression 
models to compute odds ratios (ORs) and 95% confidence intervals (CIs) for the 
association between fluoroquinolone exposure and hepatotoxicity.24  Potential 
confounding factors assessed included age, gender, race and ethnicity, history of 
alcohol-related or alcohol dependency treatment, smoking status, illicit drug use, 
comorbidities (history of diabetes, renal diseases, hypotension, heart failure, gall 
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bladder disease), or use of other hepatotoxic drugs (tetracyclines, macrolides, 
amoxicillin, amoxicillin/clavulanic acid, isoniazid , rifampicin, pyrazinamide, 
ethambutol, antifungal medications, thiazolidinediones, metformin, proton pump 
inhibitors [PPIs], and phenytoin) in the 180 days prior to admission.  Significant factors 
from bivariate analyses were entered into a multivariable regression model using a non-
computer generated, forward entry method.24  Subgroup analyses were conducted to 
study the association between each drug (ciprofloxacin, levofloxacin, and moxifloxacin) 
and their individual risk of hepatotoxicity.  All statistical analyses were conducted with 
a two-tailed α-value of 0.05 using SAS version 9.1.3 (SAS Institute, Inc, Cary, NC). 
 
Results 
We identified 21,404 patients with hepatotoxicity during the study period.  Of these 
patients, 45% (n=9,543) had liver cirrhosis and hepatotoxicity secondary to alcohol, 6% 
(n=1,302) had viral hepatitis, 5% (n=1,033) had liver cancer, 2% (n=349) had HIV/AIDS 
or Wilson’s disease, 1% (n=231) had a liver abscess or acetaminophen induced 
hepatotoxicity, and 5% (1,084) had a hospital admission in the preceding 180 days.  The 
remaining 7,862 patients were included in the final analysis as cases and were matched 
on admission date to 45,512 controls. 
 The majority of study patients were white (63.4%), males (97.7%), with a mean 
age of 61 years.  Several significant (p<0.01) variations in demographics and clinical 
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characteristics existed between cases and controls, including age, sex, race and ethnicity, 
comorbidities, substance use, and previous medication exposures (Table 2).  Diabetes 
(22.7% vs. 33.0%) was more common in the control group, while renal disease was more 
frequently reported among cases (13.0% vs. 6.0%).  Cases were more likely to abuse 
alcohol (6.3% vs. 0.6%) and illicit drugs (1.8% vs. 0.4%), and controls were more likely to 
smoke tobacco (10.2% vs. 12.9%).  More controls were recently exposed to 
thiazolidinediones (1.5% vs. 3.0%), metformin (4.5% vs. 10.0%), statins (9.2% vs. 23.0%), 
and proton pump inhibitors (10.9% vs. 14.3%).  Other comorbidities and clinical 
characteristics were similar between cases and controls. 
The findings from the unadjusted and multivariable analyses are presented in 
Table 3.  Fluoroquinolone use was associated with a 20% increased risk of 
hepatotoxicity development as compared to controls after adjusting for all potential 
confounders (OR 1.20, 95% CI 1.04-1.38).  Our subgroup analyses estimated the risk of 
hepatotoxicity associated with each individual drug of interest (ciprofloxacin, 
levofloxacin, and moxifloxacin) (Table 4).  Patients taking ciprofloxacin were 1.29 times 
more likely to develop hepatotoxicity than controls (95% CI 1.05-1.59).  Levofloxacin 
and moxifloxacin use were not associated with a significantly increased risk of 
hepatotoxicity relative to controls.  There was no collinearity between the variables in 
our model. 
10 
 
 
 
Presented in Table 3 are the odds ratios of study variables associated with 
hepatotoxicity.  Women were more likely to develop hepatotoxicity than men (OR 1.51, 
95% CI 1.30-1.75).  Black, Hispanic, Asian, and Native American patients were all more 
likely to develop hepatotoxicity than Caucasian patients.  Alcohol abusers had nearly an 
8 fold increased likelihood of hepatotoxicity development as compared to non-abusers 
(OR 7.77, 95% CI 6.63- 9.11).  Renal disease and gall bladder disease were predictive of 
the development of hepatotoxicity, while diabetes was protective against 
hepatotoxicity.  Interestingly, previous antifungal use was the only other medication 
exposure, besides fluoroquinolone use, that was predictive of hepatotoxicity in our 
study (OR 1.67, 95% CI 1.03-2.69).   
Discussion 
The literature supporting fluoroquinolone induced hepatotoxicity is limited 
primarily to case reports and reviews.6-17  To our knowledge, this is the first 
pharmacoepidemiologic study to investigate the risk of liver injury associated with 
fluoroquinolone antibiotic utilization in adult VA patients.  Overall, we found that 
patients exposed to fluoroquinolones (including ciprofloxacin, levofloxacin, and 
moxifloxacin) had a 20% increased likelihood of developing hepatotoxicity than persons 
not exposed to these agents.  While gatifloxacin was used during our study period, it 
was not included in our analysis, because it was removed from the market in 2006 due 
to an increased risk of dysglycemia.1 
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The pathophysiology of fluoroquinolone hepatotoxicity is not well understood.  
There is a higher incidence of liver damage in molecules (temafloxacin and 
trovafloxacin) that generate reactive intermediates, and this mechanism may be 
applicable to other fluoroquinolones.25-27  It may also be a hypersensitivity reaction, as 
frequent immunologic features and increased injury on re-exposure have been 
described.10  However, it is likely that fluoroquinolone liver toxicity is predominantly 
idiosyncratic.10, 28  
A "class-effect" of fluoroquinolone induced liver injury has been supported in a 
review by the national Drug-Induced Liver Injury Network.9  In their study, 
fluoroquinolones were listed as a potential cause of hepatotoxicity in 30 cases.  In our 
subgroup analyses, only ciprofloxacin was associated with a statistically significant 
increased risk of liver injury as compared to controls.  These differences between 
individual agents may be a result of utilization, rather than hepatotoxicity potential.10  
In the United States, from 1996 to 2001, prescriptions written for ciprofloxacin exceeded 
that of levofloxacin and moxifloxacin by over 40 million and 60 million, respectively.29  
The reporting rates of acute liver failure to the Food and Drug Administration per 10 
million prescriptions are similar for several fluoroquinolones, specifically reporting 
rates for levofloxacin and moxifloxacin were 2.1 and 6.6 per 10 million prescriptions, 
respectively.30  However, these are reporting rates and not incidence rates, and as such 
these figures do not represent the risk of hepatotoxicity associated with the drugs as 
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other factors such as patient co-morbidities may impact rates.  The overall incidence 
rate of acute liver injury associated with fluoroquinolones ranges from less than 1 to 6 
cases per 100,000 exposures.18, 31 
In contrast to our findings, a population-based Canadian case-control study18 
found that moxifloxacin (OR 2.20, 95% CI 1.21-3.98) and levofloxacin (OR 1.85, 95% CI 
1.01-3.39) use were significantly associated with an increased risk of hospital admission 
for acute liver injury compared to clarithromycin in patients aged 66 years and older.  
However, ciprofloxacin use was not significantly associated with this risk.  These 
conflicting results may be related to age and gender differences between the two study 
populations.  The Canadian study limited their analysis to older adults, and thus the 
patients in our study were younger (mean age of cases 77.4 ± 7.9 years compared to 58 ± 
12.7 years).  Further, our study was conducted in a largely male population, where 
96.3% of our cases were male, compared to 52.8% in the other case-control study.  
Additionally, differences in control selection between the two studies may account for 
differences.  In case-control studies, selection of an appropriate control can be 
challenging.  Population controls, as compared to hospital controls, may not reflect the 
underlying health status of cases which affects confounding, potentially biasing the 
results away from the null.18  Alternatively, use of patients with myocardial infarctions 
as the control group may be limited.  Ischemic injury to the liver may result from 
cardiogenic shock, which is a common complication of severe myocardial infarctions.32  
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If this were to affect our study results, we'd expect it to pull the measure of association 
towards the null, indicating a lesser association with fluoroquinolones.  
In our study, younger, female, non-Caucasian subjects were at an increased risk 
of hepatotoxicity.  Age was protective against the development of hepatotoxicity.  While 
advanced age is widely considered a risk factor for drug induced liver toxicity for a 
number of compounds, younger age is a risk factor for certain agents including aspirin 
and valproic acid.4, 33-35  Moreover, younger patients may have a higher risk of purely 
idiosyncratic drug-induced liver injury.33  While only 5% of patients in our analysis 
were female, we were able to demonstrate that females were more likely to develop 
hepatotoxicity than males, which is similar to previous findings.4, 33, 36  Race and 
ethnicity was associated with an increased likelihood of hepatotoxicity development.  
Genetic variability has been described as the most important risk factor for 
hepatotoxicity.37, 38  Genetic polymorphisms influence drug metabolism and may affect a 
patient’s risk of liver toxicity.39 
Our analysis demonstrated that alcohol abuse was associated with an increased 
risk of hepatotoxicity, while smoking was protective.  Previous literature supports the 
increased likelihood of hepatotoxity we observed in alcohol abusers.4, 40, 41  Some 
research suggests cigarette smoke could contain hepatotoxic compounds and that 
smoking may be a risk factor for hepatotoxicity.40, 42  This relationship, however, is not 
well described and requires further investigation.  There is the potential that we may 
14 
 
 
 
have underestimated the prevalence of these behaviors due to underreporting or lack of 
documentation with ICD-9-CM codes. 
Antifungal use was the only other medication exposure, besides fluoroquinolone 
use, which was associated with an increased risk of hepatotoxicity development in our 
study.  This increased risk of hepatotoxicity with antifungals, especially the azole 
antifungals, is well described in the literature.43  We observed a protective effect against 
hepatotoxicity development with statin, metformin, and PPI exposures.  Statin use has 
been associated with mild elevations in hepatic aminotransferases and as such statin 
package inserts contain hepatotoxicity warnings.44  Postmarketing experience however, 
suggests that liver failure due to statin use is quite low, with a reported incidence of just 
one case per million person-years of use.45  Metformin and PPI induced hepatotoxicity 
are not well recognized with suggestive evidence limited to selected case reports.46, 47  
However, all PPI use may not have been captured as patients may purchase these drugs 
over-the-counter.  
Our study had several limitations.  Firstly, enzyme levels were not available.  
Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and 
bilirubin elevations are the most commonly reported enzyme abnormalities associated 
with fluoroquinolones use.28, 48  Previously reported cases of potential fluoroquinolone 
induced hepatotoxicity were marked by elevations in these enzymes.9  Additionally, we 
were not able to assess the time between drug initiation and the development of 
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hepatotoxic symptoms.  In general, this period is highly variable for antibiotic induced 
hepatotoxicity, ranging from rapidly after administration to months after cessation of 
therapy.4  The median time between initiation of the drug and symptom development 
has been reported as eight days, with a range from 1 to 39 days.9  However, there has 
been a case report of delayed cholestatic liver disease occurring after 6 months of 
treatment with ciprofloxacin.49  To avoid missing cases of late onset disease, we 
included patients admitted within 6 months of fluoroquinolone prescription receipt.  By 
using such a broad time period it is possible that cases of  hepatotoxicity may be 
unrelated to the fluoroquinolone exposure, but we attempted to control for this through 
exclusion of other causes of liver disease and adjusting for potential confounders.   
By using administrative data we were unable to validate fluoroquinolone 
adherence.  Moreover, exposures were not adjusted for dose or duration.  There is 
evidence however that the mechanism of toxicity is predominantly idiosyncratic and 
not dose-dependent.10, 28   Confounding by indication can also not be excluded, as 
infection itself can predispose patients to hepatotoxicity.  Patients with serious 
infections or with underlying comorbidities may have been more likely to receive 
fluoroquinolone antibiotics than other narrow spectrum agents and thus been more 
likely to develop the outcome of interest.  Additionally, while which antimicrobial 
agents to carry on formulary is not a national decision throughout the VA and is rather 
a local/regional decision based on local susceptibility data, it is possible that more 
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expensive brand name fluoroquinolones (moxifloxacin and levofloxacin) were reserved 
for sicker patients.  However, we would have thus expected a larger association with 
moxifloxacin and levofloxacin than ciprofloxacin.  Furthermore, we excluded patients 
with recent hospital admissions to avoid including patients that may have already been 
ill.    
The accuracy of our findings may be affected by varying coding practices among 
institutions.   There is the potential that demographic and clinical characteristics may 
have been miscoded, however the disease coding in the VA database has been validated 
for a number of conditions and is determined to be of high quality.28, 50-52  While the 
sensitivity and specificity of hepatotoxicity diagnosis codes are not well-defined, the 
positive predictive value for acetaminophen-induced hepatotoxicity is high (95%).53  
Still, diagnosis codes may not be the most accurate method to identify rare drug 
induced liver injury since diagnosing such conditions can be challenging.54   
Although there were several significant baseline differences between cases and 
controls, we used multivariable models to adjust for these confounders.  As with other 
observational studies, residual confounding by unobserved covariates cannot be 
excluded.  Finally, the generalizability of our analysis is limited to our VA patient 
population. 
In conclusion, fluoroquinolone use was significantly associated with an increased 
risk of developing hepatotoxicity compared to non-use in our large, national 
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pharmacoepidemiologic safety study.  At present, while fluoroquinolones are generally 
believed to be safe and well tolerated, clinicians must be conscious of the potential risks 
of use including potential fluoroquinolone-induced hepatotoxicity.  Further 
comprehensive pharmacoepidemiologic analyses and multicenter surveillances are 
warranted to confirm these findings and better understand the pathogenesis of this rare 
adverse event. 
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